MX9705649A - Compuestos de fenilo substituidos como antagonistas de endotelinas. - Google Patents

Compuestos de fenilo substituidos como antagonistas de endotelinas.

Info

Publication number
MX9705649A
MX9705649A MX9705649A MX9705649A MX9705649A MX 9705649 A MX9705649 A MX 9705649A MX 9705649 A MX9705649 A MX 9705649A MX 9705649 A MX9705649 A MX 9705649A MX 9705649 A MX9705649 A MX 9705649A
Authority
MX
Mexico
Prior art keywords
aryl
heteroaryl
optionally substituted
substituted phenyl
compounds
Prior art date
Application number
MX9705649A
Other languages
English (en)
Inventor
Barry Porter
Christopher Smith
Roger John Aitchison Walsh
Tahir Nadeem Majid
Clive Mccarthy
Neil Victor Harris
Peter Charles Astles
Iain Mcfarlane Mclay
Andrew David Morley
Original Assignee
Rhone Poulenc Rorer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9501635.8A external-priority patent/GB9501635D0/en
Priority claimed from GBGB9504061.4A external-priority patent/GB9504061D0/en
Priority claimed from GBGB9509604.6A external-priority patent/GB9509604D0/en
Application filed by Rhone Poulenc Rorer Ltd filed Critical Rhone Poulenc Rorer Ltd
Publication of MX9705649A publication Critical patent/MX9705649A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30Oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • C07C255/49Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/54Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61Halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/08Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D275/00Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/12Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/54Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D411/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/12Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion describe compuestos de formula (I): en donde R1 es CN, CH2CN, CH=CHCN, CHO, o CH=CHCO2H, R2 es arilo-alcoxi inferior, heteroarilo-alcoxi inferior, arilo-alquiltio inferior o heteroarilo-alquiltio inferior, en los cuales cada una de las porciones de arilo y heteroarilo está opcionalmente substituida, R3 es halogeno, R4 es arilo opcionalmente substituido o heteroarilo opcionalmente substituido, R5 es carboxi o un isostero de ácido, X es oxígeno o azufre, y n es cero o 1; y sus N-oxidos y prodrogas, y las sales farmacéuticamente aceptables de los mismo. Los compuestos tienen actividad de antagonistas de endotelinas, y son utiles como compuestos farmacéuticos.
MX9705649A 1995-01-27 1997-07-25 Compuestos de fenilo substituidos como antagonistas de endotelinas. MX9705649A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9501635.8A GB9501635D0 (en) 1995-01-27 1995-01-27 Chemical compounds
GBGB9504061.4A GB9504061D0 (en) 1995-03-01 1995-03-01 Chemical compounds
GBGB9509604.6A GB9509604D0 (en) 1995-05-11 1995-05-11 Chemical compounds

Publications (1)

Publication Number Publication Date
MX9705649A true MX9705649A (es) 1998-07-31

Family

ID=27267564

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9705649A MX9705649A (es) 1995-01-27 1997-07-25 Compuestos de fenilo substituidos como antagonistas de endotelinas.

Country Status (18)

Country Link
EP (1) EP0805802B1 (es)
JP (1) JP3901729B2 (es)
KR (1) KR19980701690A (es)
AT (1) ATE195516T1 (es)
AU (1) AU706940B2 (es)
BR (1) BR9606961A (es)
CA (1) CA2211646C (es)
CZ (1) CZ223697A3 (es)
DE (1) DE69609812D1 (es)
EA (1) EA000061B1 (es)
FI (1) FI973111A (es)
HU (1) HUP9801938A3 (es)
IL (1) IL116907A0 (es)
MX (1) MX9705649A (es)
NO (1) NO973441L (es)
NZ (1) NZ298853A (es)
PL (1) PL184060B1 (es)
WO (1) WO1996022978A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6030975A (en) * 1997-03-14 2000-02-29 Basf Aktiengesellschaft Carboxylic acid derivatives, their preparation and use in treating cancer
CZ299741B6 (cs) 1997-09-26 2008-11-05 Abbott Gmbh & Co. Kg Kombinace endotelinového antagonisty a RAS inhibitoru a její použití, farmaceutický prostredek s jejím obsahem a zpusob výroby tohoto prostredku
DE19743143A1 (de) 1997-09-30 1999-04-01 Knoll Ag Pharmazeutische Kombinationspräparate
DE19743142A1 (de) * 1997-09-30 1999-04-01 Knoll Ag Pharmazeutische Kombinationspräparate
WO1999048530A1 (en) * 1998-03-23 1999-09-30 Merck & Co., Inc. Combination therapy for the treatment of benign prostatic hyperplasia
US6410554B1 (en) 1998-03-23 2002-06-25 Merck & Co., Inc. Combination therapy for the treatment of benign prostatic hyperplasia
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
RS95304A (en) * 2002-05-07 2006-12-15 Altana Pharma Ag. New combination fortreating airway disorders
AU2003229771A1 (en) * 2002-05-07 2003-11-11 Altana Pharma Ag Combination of a proton pump inhibitor and a respiratory agent for the treatment of respiratory diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT617001E (pt) * 1993-03-19 2000-06-30 Merck & Co Inc Derivados do acido fenoxifenilacetico

Also Published As

Publication number Publication date
HUP9801938A2 (hu) 1999-05-28
EP0805802B1 (en) 2000-08-16
JPH10513158A (ja) 1998-12-15
WO1996022978A1 (en) 1996-08-01
EA199700147A1 (ru) 1997-12-30
DE69609812D1 (de) 2000-09-21
FI973111A0 (fi) 1997-07-25
NZ298853A (en) 1998-07-28
CA2211646A1 (en) 1996-08-01
PL321545A1 (en) 1997-12-08
HUP9801938A3 (en) 1999-10-28
BR9606961A (pt) 1997-11-04
KR19980701690A (ko) 1998-06-25
JP3901729B2 (ja) 2007-04-04
AU706940B2 (en) 1999-07-01
PL184060B1 (pl) 2002-08-30
CA2211646C (en) 2008-09-09
EP0805802A1 (en) 1997-11-12
FI973111A (fi) 1997-09-25
IL116907A0 (en) 1996-05-14
ATE195516T1 (de) 2000-09-15
AU4454196A (en) 1996-08-14
NO973441L (no) 1997-09-15
NO973441D0 (no) 1997-07-25
EA000061B1 (ru) 1998-04-30
CZ223697A3 (en) 1997-12-17

Similar Documents

Publication Publication Date Title
ATE37375T1 (de) Phosphonyl-hydroxyacyl-aminosaeure-derivate und ihre verwendung als antihypertensiva.
DE69628019D1 (de) Chinolone und deren therapeutische verwendung
ATE356813T1 (de) Anilidderivate, deren herstellung und verwendung
MX9709951A (es) Derivados de benzamida y su uso como antagonistas de vasopresina.
MXPA02012314A (es) Compuestos de 1,2-dihidropiridina, metodo de fabricacion y utilizacion de los mismos.
ATE226208T1 (de) 4-oxo-4,7-dihydro-thieno(2,3-b)pyridin-5- carboxamide als antivirale mittel
ATE219077T1 (de) Endothelin antagoniste
DE59702414D1 (de) Dipeptidische benzamidine als kininogenasen-inhibitoren
ATE171158T1 (de) Substituierte phenylverbindungen
DE69924292D1 (de) Pyrazol verbindungen und ihre verwendung
MX9705649A (es) Compuestos de fenilo substituidos como antagonistas de endotelinas.
NO20020886L (no) Nye integrin- <alfa>v<beta>3-inhibitorer
DE69526097D1 (de) Bicyclische carboxamide als 5-ht1a rezeptoren liganden
PL345966A1 (en) N-substituted azabicycloheptane derivatives, production and use thereof
ATE119523T1 (de) Isochinolinderivate und ihre salze als proteasehemmer.
PT953563E (pt) Processo para a preparacao de derivados de depsipeptidos e novos compostos intermediarios para essa preparacao
AR006754A1 (es) Derivados de quinoxalina utiles en terapia
TR200001365T2 (tr) Yeni heterosiklik ikame edilmiş a-hidroksikarbonik asit türevleri
ES2182775T3 (es) Derivados de ciclohexano 1,4-disustituidos para el tratamiento de la depresion.
MX9204939A (es) Inhibidores 5-bis-aminometilen-1,3-dioxan-4,6-diona n,n',n'-trisubstituidas, de la acil coenzima a: colesterol-aciltransferasa.
BG105329A (en) N-substituted azabicycloheptane derivatives, production and use thereof